The tweet was deleted by the author.
But we saved everything 🙂.
Moderna announced detailed positive results from a Phase 3 study of its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, evaluated in combination with Merck's KEYTRUDA. The stock is down 19.3% on the day at $198.34.
Moderna announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene, also known as mRNA-4157 or V940. The investigational mRNA-based individualized neoantigen therapy was evaluated in combination with KEYTRUDA, Merck's anti-PD-1 therapy. The announcement was made by the company.
View post on X Loading...
Price is sitting right at resistance from the Ichimoku Kijun at $198.48. Shares of Moderna show a split daily structure, with price below the MA-20 but above the MA-50 and MA-200. RSI at 68.6 is nearing overbought territory, an early indication the recent advance may be getting stretched.
A close above $198.48 would show buyers are willing to follow through. During the session, Moderna stock lost the MA-20 at $209.51 after previously closing above it. Even so, over the next five trading days, the upside probability is more than 80% and the downside probability is less than 20%, with an expected trading range of $178.16 to $218.51. A drop below $165.45 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Earlier, analysts noted that Moderna's technical strength and institutional interest were supported by its upcoming inclusion in the Nasdaq-100. The latest clinical update and subsequent price action now shift focus to whether shares can sustain above $198.48, with the next decisive move likely to set the immediate trading range between $178.16 and $218.51.